Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.35 USD
Change Today 0.00 / 0.00%
Volume 19.0K
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

aeolus pharmaceuticals inc (AOLS) Key Developments

Aeolus Pharmaceuticals Inc. Receives Orphan Drug Designation from US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis

Aeolus Pharmaceuticals Inc. announced that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration granting Orphan Drug Designation for AEOL 10150 'for treatment of idiopathic pulmonary fibrosis'. Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits. The company is also developing AEOL 10150 as a treatment for cancer patients receiving radiation therapy and for the pulmonary and delayed effects of acute radiation exposure under a five-year contract with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services.

Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014

Aeolus Pharmaceuticals Inc. announced unaudited consolidated financial results for the first quarter ended December 31, 2014. For the quarter, the company reported a net loss of approximately $698,000 or $0.01 per share compared to $695,000 or $0.01 per share, for the three months ended December 31, 2013. Revenue was approximately $925,000 versus revenue of $793,000 for the three months ended December 31, 2013. Loss from operations was $698,000 against $695,000 a year ago. Net cash used in operating activities was $1,070,000 against $335,000 a year ago.

Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014

Aeolus Pharmaceuticals Inc. announced consolidated earnings results for the fourth quarter and full year ended September 30, 2014. For the fourth quarter of fiscal year 2014, total revenues were $2,417,000 as compared to $883,000 in the fourth quarter of fiscal year 2013. Net loss for the fourth quarter in fiscal year of 2014 was $524,000 or ($0.0/share) as compared to $668,000 or ($0.0/share) in the fourth quarter of fiscal year 2013. For the year, the company reported contract revenue of $9,631,000 compared to $3,928,000 a year ago. Loss from operations was $80,000 compared to $2,698,000 a year ago. Net loss was $80,000 or $0.00 per basic and diluted share compared to $3,208,000 or $0.03 per basic and diluted share a year ago. Net loss attributable to common stockholders was $80,000 compared to $3,208,000 a year ago. Net cash provided by operating activities was $323,000 compared to net cash used in operating activities of $2,970,000 a year ago.

Aeolus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt

Aeolus Pharmaceuticals Inc. filed its 10-K on Dec 22, 2014 for the period ending Sep 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Aeolus Pharmaceuticals Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 11:00 AM

Aeolus Pharmaceuticals Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 11:00 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: David C. Cavalier, Chairman of The Board, Chief Financial Officer and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AOLS:US $0.35 USD 0.00

AOLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AOLS.
View Industry Companies
 

Industry Analysis

AOLS

Industry Average

Valuation AOLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 44.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEOLUS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.